Related Experiment Video
Updated: May 31, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
[A case of marked efficacy of low-dose UFT against metastatic bladder cancer]
Makoto Satoh1, Osamu Nakano, Masaaki Kuwahara
1Dept. of Urology, Sen-en General Hospital, Tohoku University Graduate School of Medicine.
Abstract:
The two regimens of treatment consisted of either cisplatin and gemcitabine or methotrexate, vinblastine, doxorubicin and cisplatin(M-VAC), which has been widely adopted for muscle-invasive bladder cancer. But because of its potential toxicity, its tolerability has been troublesome, especially for very elderly patients. Herein, we report a bladder cancer case with multiple metastases which were controlled by low-dose UFT. At the same time, the chemosensitivity of 5-FU combined with uracylor 5-chloro-2, 4-dihydroxypyridine(CDHP). Four invasive bladder cancer cell lines were evaluated with a collagen gel droplet embedded drug sensitivity test(CD-DST). Three of four cell lines showed an increasing sensitivity to 5-FU with the combination of uracilor CDHP. Examinations with CD-DST may provide important scientific evidence for determining suitable chemotherapy for patients with advanced bladder cancer.
